Cargando…
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatoce...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Associação Brasileira de Divulgação Científica
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089232/ https://www.ncbi.nlm.nih.gov/pubmed/27783808 http://dx.doi.org/10.1590/1414-431X20165504 |